Syncor International Quarterly Profit Up 39%

Syncor International Corp. in Chatsworth said its fiscal second-quarter profit jumped 39% from a year earlier on a 20% increase in sales.

The provider of specialized pharmaceuticals said net income in the quarter ended Nov. 30 climbed to $2.11 million from $1.52 million a year earlier, while sales rose to $60.8 million from $50.6 million.

Syncor said the gains partly reflected strong sales of cardiac imaging products, which are used for evaluating heart-related conditions, though it cautioned that the sales rate “has slowed from the prior year.”

For the first half of its fiscal year, Syncor’s profit rose 39%, to $4.35 million from $3.13 million a year earlier, and its six-month sales advanced 23%, to $120.4 million from $97.9 million.

Separately, Imcera Group Inc. said its Mallinckrodt Medical unit has authorized Syncor to distribute its so-called renal imaging agent, which enables nuclear-medicine doctors to obtain diagnostic images of kidneys and the renal system for evaluation. The agreement is effective Feb. 1.